Hyperphagia: Clinical Trials

12 trials for Hyperphagia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 terminated. 12 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Terminated 12
Phase 22Terminated 2

Follow Hyperphagia: new trials by email Literature Review of Hyperphagia trials Research Report on Hyperphagia

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
Placebo, ARD-101 - Hyperphagia, Prader-Willi Syndrome
Phase 3TerminatedAardvark Therapeutics, Inc.682024-12-202026-06-30
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
ARD-101 - Hyperphagia, Prader-Willi Syndrome
Phase 3TerminatedAardvark Therapeutics, Inc.192024-07-232026-06-30
Oral Naltrexone In Pediatric Eating Disorders
Naltrexone Hydrochloride, Control - Anorexia Nervosa/Bulimia, Anorexia in Adolescence
Phase 2 / Phase 3TerminatedRosemary Claire Roden92022-04-222025-08-19
Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome
Livoletide, Placebo - Prader-Willi Syndrome, Hyperphagia
Phase 2 / Phase 3TerminatedMillendo Therapeutics SAS1582019-03-252021-02-17
Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck
Standard care of parenteral nutrition, Parenteral over night nutrition, Cetuximab - Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV
Phase 3TerminatedArbeitsgemeinschaft medikamentoese Tumortherapie82017-02-032020-05-01
Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants
Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20% - Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
Phase 3TerminatedFresenius Kabi2042015-12-012022-01-05
Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function
soybean oil (SO)-based IVFE (Medialipide), fish oil (FO)-containing IVFE (Lipidem) - Intestinal Diseases
Phase 3TerminatedHospices Civils de Lyon132015-01-012018-02-28
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension - Prader-Willi Syndrome, Obesity
Phase 3TerminatedZafgen, Inc.1082014-09-012017-01-26
Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition
Soybean oil (Standard treatment), Soybean oil + Fish oil - Total Parenteral Nutrition-induced Cholestasis
Phase 3TerminatedJohane Allard22012-02-012016-05-12
Total Parenteral Nutrition Associated Cholestasis (TPNAC) and Plasma Amino Acid Levels in Neonates
Primene 10 % from Baxter - Premature Birth
Phase 3TerminatedCoordinación de Investigación en Salud, Mexico942011-05-012017-06-09
Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer
SMOF Kabiven - Pancreatic Cancer
Phase 3TerminatedNational Center for Tumor Diseases, Heidelberg322010-03-012014-09-25
Prader-Willi Syndrome and Appetite
Sandostatin LAR - Hyperphagia, Prader-Willi Syndrome
Phase 3TerminatedUniversity of British Columbia102004-08-012007-10-31

Narrower conditions

Prader-Willi Syndrome (5)  ·  Obesity (2)  ·  Anorexia Nervosa (1)  ·  Bulimia (1)  ·  Bulimia Nervosa (1)  ·  Carcinoma, Squamous Cell (1)  ·  Cholestasis (1)  ·  Feeding and Eating Disorders (1)  ·  Impulsive Behavior (1)  ·  Intestinal Diseases (1)  ·  Laryngeal Diseases (1)  ·  Liver Diseases (1)  ·  Pancreatic Neoplasms (1)  ·  Premature Birth (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (12)  ·  Signs and Symptoms (12)  ·  Signs and Symptoms, Digestive (12)  ·  Abnormalities, Multiple (5)  ·  Chromosome Disorders (5)  ·  Congenital Abnormalities (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Genetic Diseases, Inborn (5)  ·  Imprinting Disorders (5)  ·  Intellectual Disability (5)  ·  Nervous System Diseases (5)  ·  Neurobehavioral Manifestations (5)  ·  Neurologic Manifestations (5)  ·  Nutrition Disorders (5)  ·  Nutritional and Metabolic Diseases (5)

Interventions

Fish Oils (2)  ·  Soybean Oil (2)  ·  soybean oil, phospholipid emulsion (2)  ·  CKD732 (1)  ·  Cetuximab (1)  ·  Cisplatin (1)  ·  Emulsions (1)  ·  Fat Emulsions, Intravenous (1)  ·  Naltrexone (1)  ·  Parenteral Nutrition (1)  ·  Radiotherapy (1)  ·  SMOFlipid (1)  ·  cyclic des-acyl ghrelin (6-13) (1)  ·  fish oil triglycerides (1)

Sponsors

Aardvark Therapeutics, Inc. (2)  ·  Arbeitsgemeinschaft medikamentoese Tumortherapie (1)  ·  Coordinación de Investigación en Salud, Mexico (1)  ·  Fresenius Kabi (1)  ·  Hospices Civils de Lyon (1)  ·  Johane Allard (1)  ·  Millendo Therapeutics SAS (1)  ·  National Center for Tumor Diseases, Heidelberg (1)  ·  Rosemary Claire Roden (1)  ·  University of British Columbia (1)  ·  Zafgen, Inc. (1)

Countries

United States (6)  ·  Canada (4)  ·  Australia (3)  ·  United Kingdom (3)  ·  France (2)  ·  South Korea (2)  ·  Austria (1)  ·  Belgium (1)  ·  Germany (1)  ·  Italy (1)  ·  Mexico (1)  ·  Netherlands (1)  ·  Spain (1)

Top investigators

Dennis Kim, MD (1)  ·  Didier Barnoud, MD (1)  ·  Felix Keil, Prof.Dr. (1)  ·  Jean-Pierre Chanoine, MD (1)  ·  Johane P Allard, MD,FRCPC (1)  ·  Rosemary C Roden, MD (1)  ·  Steven A Abrams, MD (1)

Results publications

PMID 28556449, PMID 33006765, PMID 36167287, PMID 39374788